Aprea director granted RSUs and stock options
Aprea Therapeutics director Jean-Pierre Bizzari received new equity awards.
Rhea-AI Filing Summary
Aprea Therapeutics director Jean-Pierre Bizzari received new equity awards. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, if he continues serving on the board and certain acceleration conditions do not apply.
He also received stock options covering 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under the same service-based conditions. Following the grant, he directly holds 4,180 common shares, and the options expire on June 16, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 15,690 shares
Grant/Award
2 txns
Insider
BIZZARI JEAN-PIERRE
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 12,555 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 3,135 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to Buy) — 12,555 contracts (Direct);
Common Stock — 4,180 shares (Direct)
Footnotes (2)
- F1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
- F2. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Key Figures
Restricted stock units granted: 3,135 units
Stock options granted: 12,555 options
Option exercise price: $0.7293 per share
+3 more
6 metrics
Restricted stock units granted
3,135 units
Granted June 16, 2026; vest June 16, 2027
Stock options granted
12,555 options
Granted June 16, 2026; vest June 16, 2027
Option exercise price
$0.7293 per share
Stock options on Aprea Therapeutics common stock
Option expiration date
June 16, 2036
Final date to exercise the 12,555 options
Shares held after grant
4,180 shares
Aprea Therapeutics common stock held directly by Bizzari
Transaction direction
2 acquisitions
Compensation-related grants, not open-market buys
Key Terms
restricted stock units, vest, stock options, exercise price
4 terms
restricted stock units financial
"These shares represent restricted stock units which were granted on June 16, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vest financial
"which will vest and be settled in common stock on June 16, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
stock options financial
"The option vests in full on June 16, 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"conversion_or_exercise_price: "0.7293""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Aprea Therapeutics (APRE) director Jean-Pierre Bizzari receive?
Jean-Pierre Bizzari received 3,135 restricted stock units and stock options for 12,555 shares. The RSUs settle in common stock, and the options give him the right to buy shares at a fixed exercise price if they vest.
When do Jean-Pierre Bizzari’s new Aprea Therapeutics (APRE) RSUs and options vest?
Both the 3,135 restricted stock units and the 12,555 stock options vest in full on June 16, 2027. Vesting requires his continued service on Aprea Therapeutics’ board through that date, subject to possible acceleration in certain circumstances.
What is the exercise price of Jean-Pierre Bizzari’s new Aprea Therapeutics (APRE) stock options?
The newly granted stock options have an exercise price of $0.7293 per share. This means he can choose to buy Aprea Therapeutics common shares at $0.7293, once the options vest and before they expire, if he decides to exercise them.
Are Jean-Pierre Bizzari’s Aprea Therapeutics (APRE) awards open-market purchases or compensation grants?
The awards are compensation-related grants, not open-market purchases. The Form 4 shows transaction code “A” for grant or award, covering 3,135 restricted stock units and 12,555 stock options, all subject to future vesting conditions tied to board service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
